Monday, November 14, 2011

Stem cell pioneer Geron to focus on cancer, cut 66 jobs

Pioneering stem cell drug developer Geron Corp. said it will axe 66 jobs, halt its stem cell R&D programs and seek buyers for those assets.
The Menlo Park company (NASDAQ: GERN) said it will concentrate on cancer treatments that could produce milestone events over the next 20 months. While researchers stress the promise of stem cells, treatments using embryonic stem cells could be several years in the future.

No comments:

Post a Comment